EVHA T01: Therapeutic HIV Vaccine Trial

Phase 2, randomised, double-blind trial of GTU-MultiHIV B clade vaccine, MVA-B and vedolizumab in human immunodeficiency virus infection (HIV) (4 arms), sponsored by ANRS. Primary endpoints: Time from treatment interruption to the earliest of reaching HIV RNA >= 10,000 copies/ml or resuming antiretroviral therapy at 24 weeks and A clinical decision to discontinue the regimen for an adverse event that is considered related to product. Started Feb 2019; status: terminated.